WinstonWınston
Back
Stock

Takeda Pharmaceutical Company Limited

TAK
49
Drug Manufacturers - Specialty & Generic · Healthcare
Price
$19.67
+0.22 (+1.13%)
Market Cap
$62.60B
Exchange
New York Stock Exchange
Winston Score
49
Winston is serious
Mixed quality — meaningful strengths and weaknesses.
Data as of Oct 18, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Good
15/30
Growth
Good
10/20
Cash Flow
Exceptional
9/10
Stability
Mixed
4/10
Valuation
Good
5/10
Ownership
Weak
2/15
Dividends
Strong
4/5

49 of 100 counted points = Winston Score 49.

Track this stock — start free trial

Share count rising — dilution

+1.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 3.15B (2022) → 3.21B (2026)

§Winston Score History

The full picture

Takeda Pharmaceutical is a large Japanese drug company that discovers, makes, and sells prescription medicines to patients around the world. Its main focus areas include rare diseases, cancer, digestive disorders, and neuroscience, with key drugs like Entyvio (for bowel disease) and a growing rare disease portfolio. Takeda is one of the largest pharmaceutical companies in Asia and ranks among the top 15 globally by revenue.

The company earns money by selling branded prescription drugs to hospitals, clinics, and pharmacies, primarily in the United States, Europe, and Japan. Takeda's competitive position rests on its specialized drug portfolio and a significant research pipeline, though it carries a heavy debt load from its $62 billion acquisition of Shire in 2019. The biggest risk facing Takeda is patent expiration on Entyvio, its top-selling drug, which faces biosimilar competition in the coming years and currently accounts for a large share of revenue.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+10.2% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-9.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

¥716.7B/ year

→ Flat (-2% vs prior year)

15.0% of revenue

In line with sector average (18%)

Steady R&D investment year-over-year

Insider Activity

0.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~10 years

¥1.0T cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

¥1.0T cash & investments at current burn rate

Growth context

Takeda Pharmaceutical Company Limited is growing revenue at 10% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
66.7%
Premium pricing power — 66.7% gross margin
Profit after running costs
Operating Margin
16.5%
Healthy — 16.5% operating margin
Return on the money invested
ROCE
4.1%
Weak — 4.1% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+4.0%
Slow sales growth (+4.0% YoY)
Profit growth
EPS YoY
+31.9%
Earnings growing fast (+31.9% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
542%
Turns 542% of profit into real cash
Spare cash per sale
FCF Margin
12.7%
Converts sales into free cash efficiently (12.7%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.65
Moderate — manageable debt (0.65)
Covers its interest
Interest Cover
1.61x
Dangerous — barely covers interest (1.6x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
54.5x
Expensive — P/E 54.5

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year
P/E vs Forward
+28.6
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (54.5 → 25.9)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
4.04%
Healthy income — 4.04% yield

Generous yield. Worth checking whether the payout is sustainable.

Dividend record
Dividend Growth
+4.5%
Dividend growing modestly (4.5% YoY)
Payout Ratio
175%
no trend
Paying out more than the last 12 months of profit. The dividend is being funded from cash or borrowing, not this year’s earnings.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial